

**SINGAPORE  
BIOTECH INVEST**

21-22 March 2017

Singapore Exchange (SGX)

**HONG KONG  
BIOTECH INVEST**

23-24 March 2017

KPMG Hong Kong

**AUSTRALIA-CHINA  
BIOTECH INVEST**

27-28 March 2017

Shanghai Marriott Hotel City Centre

**Peter Molloy, Chief Executive Officer, Race Oncology**

Peter Molloy is the CEO of Race Oncology. Previously, he worked for 18 years in the pharmaceutical industry before joining the biotech sector. At the Australian pharmaceutical company, Faulding, he was Division Manager for the company's pharmaceutical business, then served as head of two other Faulding subsidiaries, before joining Pharmacia (now Pfizer) as Managing Director of its Australia and NZ operations, where he managed four pharmaceutical marketing divisions including oncology marketing. Promoted to Vice President of Strategic Marketing, he was then responsible for Pharmacia's marketing strategy and drug portfolio across 22 countries throughout Asia-Pacific and Latin America. Subsequently, he served as CEO of three biotechnology companies – Biota Holdings Ltd, SLIL Biomedical Corp and Florigene Ltd – where he managed numerous R&D programs, raised equity funding and executed four pharmaceutical partnerships. During his three and a half years as CEO of ASX-listed Biota, the company's market value grew from approximately \$30m to nearly \$300m. Overall, during his career, he has managed eight biotechnology or pharmaceutical operations, launched 23 pharmaceutical products, and executed 40 international licensing or distribution deals. He holds a BSc from the University of Melbourne (biochemistry/microbiology) and an MBA from the University of Adelaide. He is also a Fellow of the Australian Institute of Company Directors and has served on several Australian and US boards as chairman or non-executive director, including six years as a non-executive director of Viralytics, a successful ASX listed drug development biotech company.

